Scan this QR code to register for access to our Dossier on Duchenne muscular dystrophy, #DMD.

On #RareDiseaseDay, we are offering researchers access to a Dossier on Duchenne muscular dystrophy, #DMD, a rare, progressive neuromuscular disorder caused by mutations in the dystrophin gene.

Aganitha presents poster on: Beyond the Hype - Agentic Al for Translational R&D By: Chanukya Nanduru Aganitha.ai At: AI for Materials, Energy, and Chemical Sciences Gordon Research Conference Autonomous Discovery Across Scales Date: Thursday, 5th February 2026 Time: 04:00 PM - 06:00 PM Venue: Grand Galvez, 2024 Seawall Boulevard, Galveston, Texas, United States

📍 Aganitha AI at GRC2026

Chanukya Nanduru will be presenting a poster at the Gordon Research Conference (GRC) AIMECS 2026, showcasing real-world case studies that demonstrate how #AgenticAI delivers measurable impact across R&D workflows.

Happy Breakthroughs in 2026. May the cryptic binding sites reveal before sceptics come to your next quarterly review.

Looking forward to the most impactful scientific breakthroughs in 2026. Happy new year.

Moving beyond co-pilots, demos & pilots to R&D operating model transformation with Igniva (TM) AI Agents.

Happy new year. 2026 is the year #AI will move beyond pilots to real transformation of R&D operating models, to enable faster and better scientific breakthroughs!

Igniva™ | Agents | Aganitha Igniva™ is a suite of AI agents designed to advance therapeutic design and research across multiple disease areas.

🧬 We consolidated these lessons into Igniva, an #AgenticAI stack designed to support a true operating-model shift in translational R&D.

Not replacing scientists.
Replacing fragile ways of working.

www.aganitha.ai/products/ign...

Agentic AI in Biopharma R&D: Lessons from Embedding Agents Inside Live Programs - Aganitha AI Inc Agentic AI Is Not a Tooling Upgrade — It’s an Operating Model Shift The real promise of Agentic AI lies in its […]

If 2026 is the year you’re testing how #biopharma R&D work leverages #AI #Agents, we hope this perspective is useful.

🔗 Read the full report here: www.aganitha.ai/blogs/agenti...

Agentic AI without governance is opaque and risky. Agentic AI with governance becomes a learning system.

🛡️ Explicit support for governance of #AI #Agents

We added a #governance layer that not only provided visibility and safeguards, but also enabled institutional memory.

Scientific R&D places demands on agents that differ fundamentally from typical enterprise workflows.

🖥️ R&D workflows have special needs.

#Agents must be able to:

• Generate and interpret scientific visualizations
• Work with long-running HPC & cloud compute, staying aware of costs
• Support iterative, contextual & collaborative analysis

Disease Biomarker & Target Insights Platform & Services, DBTIPS (TM)

📚 #LLM limitations were not the only bottleneck.

Meaningful #AgenticAI in R&D required reasoning-oriented data foundations and application layers designed for thinking, not just retrieval.

We invested into curation & continuous update of disease & target‑centric intelligence.

🧩 #AgenticAI Is Not a Tooling Upgrade - It’s an Operating Model Shift

The biggest value did not come from lit. search & tool invocations. It came when agents helped scientists decide which questions matter, kept decisions tightly coupled to evidence & supported iterations.

Agentic AI Is Not a Tooling Upgrade. It’s an Operating Model Shift.

🧪 Field report from a year of Agentic AI adoption in #biopharma R&D

Over the past year, we embedded #AI #agents, using Igniva, our #AgenticAI stack, directly inside live translational R&D programs.

Here's what we learned 👇

Thanks to @pubs.acs.org for accepting #MyACSCover featuring our work.

Siponimod (red) binds strongly to both sphingosine-1-phosphate (S1P) receptor 1 (green, active) and receptor 2 (blue, inactive), but only S1PR1 undergoes the conformational changes needed for activation.

Selective Activation of GPCRs: Molecular Dynamics Shows Siponimod Binds but Fails To Activate S1PR2, Unlike S1PR1 G protein-coupled receptors (GPCRs) are central to drug discovery, accounting for nearly 40% of approved pharmaceuticals due to their regulatory role in diverse physiological processes. Given the high...

Hearty congratulations to the authors, Soniya, Kruthika, Chanukya and Antarip

pubs.acs.org/doi/10.1021/...

Unearthing the Gold Dust of Mechanistic Insight in Drug Discovery, with Deep Science & Deep Tech - Aganitha AI Inc We’re pleased to share our study, “Selective Activation of GPCRs: Molecular Dynamics Shows Siponimod Binds but Fails to Activate S1PR2, Unlike S1PR1,” […]

⛏️ Understanding how drugs modulate targets is increasingly as important as which targets they hit. This isn’t easy to figure out and deep science and deep tech are evolving fast to help find the answers.

www.aganitha.ai/blogs/uneart...

FDA’s New Plausible Mechanism Pathway | NEJM Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The FDA outlines a path to market entry for products where a randomized trial is no...

🏛️ Regulators are also signaling change. With the
@US_FDA articulating “plausible mechanism” pathways where RCTs are limited, mechanistic clarity is becoming an evidentiary asset, not a luxury.

www.nejm.org/doi/full/10....

Insights into the Mechanism of Action of Tirzepatide: A Narrative Review - Diabetes Therapy Tirzepatide is the first dual long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes in adults, f...

📈 This matters now more than ever. #GPCRs dominate today’s biggest therapeutic wins, most visibly in obesity, where how receptors are modulated drives both efficacy and tolerability.

link.springer.com/article/10.1...

⚙️ Using long-timescale molecular dynamics (#MD), ensemble analysis & #GPCR transmission-switch reasoning, we explain a clinically relevant selectivity and safety phenotype.

✨ Unearthing the Gold Dust of Mechanistic Insight With Deep Tech✨

🧪 We show this in our recently published ACS
@JCIM_JCTC paper, elucidating the mechanistic basis by which Siponimod, a drug for #multiplesclerosis (MS), avoids off-target activation.

pubs.acs.org/doi/10.1021/...

🌐Heading to #AIChEAnnual?

Meet Chanukya Nanduru to see Aganitha Igniva™ Agentic AI workflows for R&D and TechOps -

🧬 (Bio)molecular discovery & development
🧪 Structural modeling
⚗️ Catalyst / enzyme selection & optimization
💊 Formulation
🏭 Unit ops digital twins

Aganitha presents posters on Agentic-AI powered Target Elucidation for novel Peptide Therapeutics (by RajKumar Chakraborty) and Next-gen Lipid Nanoparticles (LNPs): Insights from AI/ML Methods & Molecular Simulations (by Madhura Mahole) On 25-26 September, 2025 At The Lalit, Mumbai

Meet @madhuram.bsky.social and Raj Kumar Chakraborty at the #Peptides & Complex Generics Symposium to see how Agentic & Generative #AI along with molecular simulations are accelerating Target elucidation, #LNP engineering and more for peptides & other complex biological therapeutics.

Aganitha Presents Beyond the hype: Real-world application of Agentic AI accelerating R&D and Care Prasad Chodavarapu Aganitha.ai 2025 Symposium on Artificial Intelligence and Pharmaceutical Medicine (AIPM-India) At 10:30 am on Sep 11, 2025 (Thursday) TTJ AUDITORIUM, IIT Madras

🚀Real-World Applications of #AgenticAI Accelerating #Biopharma R&D and Care

👉 Join us at AIPM-India 2025 in IIT Madras to see in action, Igniva™ AI agents, built on 5+ years of global biopharma R&D collaborations by 100+ researchers at Aganitha.

Solutions for Consumer Care R&D | Consumer Care | Aganitha Accelerate move from petroleum-derived to natural and bio-polymer ingredients, from animal testing to predictive in silico safety assessments, and from chemical cleaning agents to bio-based probiotic ...

Learn more about Aganitha solutions for #ConsumerCare R&D at www.aganitha.ai/solutions-fo...

#AI #CompChem #MultiOmics #AI4Science #Sustainability

🛠️ Aganitha AI solutions for #ConsumerCare R&D acceleration:

🧪 Surfactant discovery & optimization
⚖️ Stability profiling under real-world conditions
🧍‍♀️ Skin sensitization modeling
🌿 Biopolymer design
🦠 Microbiome analysis

Major paradigm shifts in #ConsumerCare:

🌱 Petroleum based → natural & bio-polymer
🐇 Animal testing → in silico models
🧴 Harsh chemicals → probiotics & enzymes

Aganitha accelerates this transformation through simulations, predictions, optimizations & safety models 🚀

Solutions for Consumer Care R&D | Consumer Care | Aganitha Accelerate move from petroleum-derived to natural and bio-polymer ingredients, from animal testing to predictive in silico safety assessments, and from chemical cleaning agents to bio-based probiotic ...

#ConsumerCare R&D is transforming — and Aganitha is powering the shift with #AI, #CompChem & #MultiOmics. Faster, smarter, more sustainable innovation. 🌍✨

www.aganitha.ai/solutions-fo...

Aganitha is hiring computational chemistry researchers. Apply at https://www.aganitha.ai/careers/

We're #hiring for multiple roles in our Computational Chemistry team at Aganitha (Hyderabad, India).

DISTILL™ is built from the ground up for the #LLM & #AgenticAI era. Every capability is accessible via #MCP — enabling faster, more impactful progress across disease research, target & biomarker discovery, patient stratification, & indication expansion.

#scRNAseq #RNAseq #Omics

At Aganitha, we make #AI work for science. DISTILL™ is our #SingleCell #Omics analysis platform, built to accelerate the decoding of complex biology across public and private studies — spanning species, disease contexts, and interventions.

Aganitha DISTILL™: DISTILLing complex biology in the Single cell & Agentic AI era YouTube video by Aganitha AI

🔬 DISTILLing Complex Biology in the #SingleCell & #AgenticAI Era

Why should single cell #omics analysis still take months, even in 2025?

In this video, Ananya Jana explains the challenges single cell researchers face today and how DISTLL™ accelerates journey to insights.

youtu.be/dxszTx5YjKQ